2-chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts

Cancer Research

Volumn 57, Issue 18, 1997, Pages 3895-3898

  Marcantonio, Daniela ^a   Panasci, Lawrence C ^a   Hollingshead, Melinda G ^b   Alley, Michael C ^b   Camalier, Richard F ^b   Sausville, Edward A ^b   Dykes, Donald J ^c   Carter, Christopher A ^c   Malspeis, Louis ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROETHYL 3 SARCOSINAMIDE 1 NITROSOUREA; CARMUSTINE; CHLOROETHYLNITROSOUREA DERIVATIVE; SARCOSINAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; CATECHOLAMINE RELEASE; CENTRAL NERVOUS SYSTEM TUMOR; COLONY FORMING UNIT; GLIOMA CELL; INTRAVENOUS DRUG ADMINISTRATION; LIPID SOLUBILITY; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030832163     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lesser, G. J., and Grossman, S. The chemotherapy of high-grade astrocytomas. Semin. Oncol., 21: 220-235, 1994.
2. Walker, M. D., Alexander, E., Jr, Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Jr., Norrell, H. A., Owens, G., Ransohoff, J., Wilson, C. B., Gehan, E. A., and Strike, T. A. Evaluation of BCNU and/or radiation in the treatment of anaplastic gliomas. A comparative clinical trial. J. Neurosurg., 49: 333-343, 1978.
3. Carter, K. S., Schabel, T. M., Jr., Broler, L. E., and Jonston, T. P. 1,3-bis-(2-Chloroethyl)-1-nitrosourea (BCNU) and other nitrosoureas in cancer treatment: a review. Adv. Cancer Res., 16: 273-332, 1972.
4. Walker, M. D., Green S. B., Byar, D. P., Alexander, E., Jr., Batzdorf, Mealy, J., Owens, G., Ransohoff, J., Roberston, J. T., Shapiro, W. R., Smith, K. R., Jr., Wilson, C. B., and Strike, T. A. Randomized comparisons of radiation and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med., 303: 1323-1329, 1980.
5. Suami, T., Kato, T., and Hisamatsu, T. 2-Chloroethylnitrosourea congeners of amino acid amides. J. Med. Chem., 25: 829-832, 1982.
6. Skalski, V., Rivas, J., Panasci, L. C., and Feindel, W. The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man. Cancer Chem. Pharmacol., 22: 137-140, 1988.
7. Panasci, L. C., Dufour, M., Chevalier, L., Isabel, G., Lazarus, P., McQuillan, A., Arbit, E., Brem, S., and Feindel, W. Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human gliomas compared with BCNU. Cancer Chem. Pharmacol., 14: 156-159, 1985.
8. von Hoff, D. D., Clark, G. M., Stogdill, B. J., Sarosdy, M. F., O'Brien, Casper, J. T., Mattox, D. E., Page, C. P., Cruz, A. B., and Sandbach, J. F. Prospective clinical trial of a human tumor cloning system. Cancer Res., 43: 1926-1931, 1983.
9. Begleiter, A., Lam, H-Y. P., and Goldenberg, G. J. Mechanism of uptake of nitrosourea by L5178Y lymphoblasts in vitro. Cancer Res., 37: 1022-1027, 1977.
10. Nöe, A. J., Malapetsa, A., and Panasci, L. C. Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics. Cancer Res., 54: 1491-1496, 1994.
11. Nöe, A. J., Malapetsa, A., and Panasci, L. C. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell line SK-MG-1 is mediated by an epinephrine sensitive carrier system. Mol. Pharmacol., 44: 204-209, 1993.
12. Dykes, D. J., Abbott, B. J., Mayo, J. G., Harrison S. D., Jr., Laster, W. R., Jr., Simpson-Herren, I., and Griswold, D. P., Jr. Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. In: Contributions to Oncology, Vol. 42, pp. 1-22. Basel: S. Karger AG, 1992.
13. Supko, J. G., Camalier, R. F., Hollingshead, M. G., Grever, M. R., and Malspeis, L. Activity of SarCNU against human CNS tumor xenografts and characterization of its pharmacokinetics in mice. Proc. Am. Assoc. Cancer Res., 36: 375, 1995.
14. Chen, X. P., Malapetsa, A., McQuillan, A., Marcantonio, D., Bello, V., Mohr, G., Remack, J., Brent, T. P., and Panasci, L. Evidence for nucleotide excision repair as a modifying factor of MGMT-mediated innate chloroethylnitrosourea resistance in human tumor cell line. Mol. Pharmacol., in press, 1997.
15. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res., 51: 3367-3372, 1991.
16. Freireich, E. J., Gehan, E. A., Rail, D. P., Schmidt L. H., and Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep., 50: 219-244, 1966.
17. 2 carrier, which mediated increased cytotoxicity. Cancer Chem. Pharmacol., 37: 505-508, 1996.
18. Trendelenburg, U. The extraneuronal uptake and metabolism of catecholamines. In: U. Trendelenburg and N. Weiner (eds.), Catecholamines 1, Handbook of Experimental Pharmacology, Vol. 90, pp. 279-319. New York: Springer-Verlag New York, Inc., 1988.